The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Second License Agreement with BACH for Tumor Microenvironment Targeting Technology
In December 2020, we entered into a sublicense and collaboration agreement with BACH to develop and commercialize synthetic compounds that leverage a proprietary technology platform (“Second BACH
97
TABLE OF CONTENTS
Agreement”). Under the Second BACH Agreement, we were granted an exclusive, sublicensable and worldwide license under BACH’s patent rights to use, develop, manufacture and commercialize any products arising from the patent related to the synthetic compounds. We are responsible for the costs of all preclinical and clinical development activities during the preclinical and clinical development phase of the collaboration.
For the exclusive commercialization option, we paid an upfront fee of $200,000 in January 2021. We are further obligated to make aggregate milestone payments to BACH of up to $3,000,000 for the first product developed, upon the achievement of specified development and regulatory milestones and of up to $45,000,000 upon the achievement of specified sales milestones. For subsequent products, we are obligated to make a milestone payment to BACH of up to $1,000,000 for major market regulatory approval and of up to $45,000,000 upon the achievement of specified sales milestones. We are also obligated to pay a low-teens percentage royalty which is reduced by the royalty payments made to AVACTA (defined below), related to the annual net sales by us and any of our affiliates and sublicensees based on our global sales for all products. We will pay royalties on a country-by country basis beginning upon the first commercial sale in such country. There is also an additional low- teens to mid-twenties percentage sublicense fee payable to for monetary payments arising from a grant of a sub-license to a sub-licensee or in the form of other benefits, depending on the specified development stage of the product.
We have the right to terminate the Second BACH Agreement subject to a prior written notice of 90 days to BACH. If we fail or BACH fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. The Second BACH Agreement expires upon the cessation of commercialization of the last licensed product by us. The royalty term will expire on a licensed product-by-licensed product or licensed process-by-licensed process and country-by-country basis, the time period commencing on the first commercial sale of such licensed product or licensed process in such country and continuing until the later of (i) the expiration of the last to expire Valid Claim covering the licensed product or licensed process in such country, or (ii) 10 years after the first commercial sale of the licensed product or licensed process in such country.
On January 22, 2021, we entered into a research agreement with BACH for a period of three years where BACH is contracted to perform research on our behalf, with
icense Agreement with BACH for PNT2004
In April 2020, we entered into a sublicense and collaboration agreement with Bach Biosciences Ltd. (“BACH”) to develop and commercialize radiopharmaceuticals (“BACH Agreement”). Under the BACH Agreement, we were granted an exclusive, sublicensable, worldwide license under BACH’s patent rights to use, develop, manufacture and commercialize any products arising from the licensed technology. We have the right to grant sublicenses of our rights. Under the BACH Agreement, we are responsible for the costs of all preclinical and clinical development activities during the preclinical and clinical development phase of the collaboration. We have an option of exercising the commercialization option, which allows it to commercialize any products arising from the research. For the exclusive commercialization option, we paid an upfront fee of $600,000 which gets credited against the $5,000,000 option exercise fee. If the option is exercised, we are obligated to make the aggregate milestone payments of up to $8,000,000 to BACH upon the achievement of specified development and regulatory milestones and up to $38,000,000 upon the achievement of specified sales milestones. We are also obligated to pay a low-teens percentage royalty related to the annual net sales by us and any of our affiliates and sub-licensees based on our global sales. We are responsible for all costs and expenses incurred related to the development, manufacture, regulatory approval and commercialization of all licensed products. We will pay royalties on a country-by-country basis beginning upon the first commercial sale in such country. There is also an additional low-teens to mid-twenties percentage sublicense fee payable to BACH for monetary payments arising from a grant of a sub-license to a sub-licensee or in the form of other benefits, depending on the specified development stage of the product.
We have the right to terminate the BACH Agreement, subject to a prior written notice of 90 days to BACH. If we fail or BACH fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. The BACH Agreement expires upon the cessation of commercialization of the last licensed product by us. Through December 31, 2020, we have paid BACH the $600,000 upfront fee.
Concurrently in April 2020, we entered into a research agreement with BACH for a period of 5 years where BACH is contracted to perform research on our behalf, with respect to the BACH Agreement. Under the research agreement we will make payments to BACH in accordance with an agreed upon payment schedule, upon which any sums payable will be credited against the option exercise fee under the sublicense agreement. Through December 31, 2020, we have paid $750,000 under this agreement.
Second License Agreement with BACH for Tumor Microenvironment Targeting Technology
In December 2020, we entered into a sublicense and collaboration agreement wi
https://www.sec.gov/Archives/edgar/data/1811764/000110465921098307/tm2123357-1_s1.htm
AVA6000 pro-doxorubicin, and we eagerly await the clinical data from their program as well as it may help us inform our own development plans.
License agreement with Avacta Lifesciences Limited (“AVACTA”) for Tumor Microenvironment Targeting Technology
In December 2020, we entered into an agreement with AVACTA (“AVACTA Agreement”). Under the AVACTA Agreement, we became a sublicensee of AVACTA’s license for using the intellectual property of developing and marketing radiopharmaceutical agents. Under this agreement, we obtained an exclusive license of AVACTA’s patent rights to use, develop, manufacture and commercialize any FAP-activated PSMA targeted radiopharmaceutical and a non-exclusive license of AVACTA’s patent rights for other FAP-activated radiopharmaceuticals arising from the licensed technology.
We will pay during 2021 an upfront payment of $1.0 million for the initial license fee, $250,000 of which has already been paid and the remaining payments are due upon preclinical milestones. We are further obligated to make aggregate milestone payments to AVACTA of up to $4,500,000, upon the achievement of specified development milestones for our first product and up to $3,000,000 each for any license products upon reaching the specified development milestone. In addition, we are obligated to pay a milestone payment of $5,000,000 for each product for the regulatory milestone of being approved in specified territories. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are also obligated to pay a single digit percentage royalty (subject to a reduction on certain conditions) related to the annual net sales by us, our affiliates or our sublicensees for each licensed product or license process and a single digit percentage royalty on a specified product arising out of the patents. The royalty rate will be reduced by 50% for net sales occurring in the United States if there is no valid claim at the time of sale. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are responsible for all costs and expenses incurred related to the development, manufacture, regulatory approval and commercialization of all licensed products. In January 2021, we paid $250,000 of the initial license fee.
https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
Elimination half-life (t1/2) of AVA6000 & Doxorubicin
t1/2 (Elimination half-life) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
CYCLE 1 AND CYCLE 2, 0-72 HOURS POST DOSE (DOSE ESCALATION)
Maximum drug concentration (Cmax) of AVA6000 & Doxorubicin
Cmax (maximum plasma concentration) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
CYCLE 1 AND CYCLE 2, 0-72 HOURS POST DOSE (DOSE ESCALATION)
Renal clearance (CLr) of AVA6000 & Doxorubicin
CLr (Renal clearance) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
CYCLE 1 AND CYCLE 2, 0-72 HOURS POST DOSE (DOSE ESCALATION)
Area under the concentration versus time curve (AUC) of AVA6000 & Doxorubicin
AUC (Area under the concentration versus time curve) of AVA6000 and Doxorubicin after administration after Cycle 1 and 2 for 72 hours post-dose.
CYCLE 1 AND CYCLE 2, 0-72 HOURS POST DOSE (DOSE ESCALATION)
https://www-hkn24-com.translate.goog/news/articleView.html?idxno=326755&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
Daewoong Pharmaceutical is also developing cell therapy products through Apicel Therapeutics, a joint venture established with Avacta in the UK. Apicell Therapeutics is a graft-versus-host disease using a functionally enhanced stem cell gene therapy platform (AFX platform) that introduced Avacta's 'Affimer' gene to 'DW-MSC', a stem cell platform of Daewoong Pharmaceutical. (graft-vs.-host disease) treatment is being developed.
Recently, it is accelerating the development of cell therapy-based technology, such as signing an MOU with Excel Therapeutics for 'development of a customized medium for gene-transduced stem cell therapy (AFX platform application)'.
?? : ???????(http://www.hkn24.com)
Please Add but this is what I expect over the coming weeks inflection points ...
USA onboard Trials
last 2 UK Hosp Added
DE anytime
Launch SOT / GvHD Pre Clinical http://affyxell.com/pipeline/pipeline.php
Point Canseek update
LG Chem Update
AffidX Update / Launch
Updates on All ...... https://avacta.com/therapeutics/pipeline/
No doubt iv'e missed a few but any of the Above Imminent IMHO
Very interesting are they referring to our Affimer ?
For example, protein A binding capacities have increased from 20 mg/mL to =100 mg/mL.
https://www.astreabioseparations.com/resources/articles/reducing-cell-and-gene-therapy-development-time-and-cost-with-new-purification-strategies
Thankyou
Alternatively, the Affimer ® Ligands, developed by Avacta, and licensed by Astrea have exquisite selectivity, good chemical and thermal stability, broad tolerance to organic solvents and wide range of pH values. Again, the library is highly diverse with 10 10 ligands.
Here we showcase examples from our Synthetic Ligand and Affimer ® Ligand discovery platforms, demonstrating the process from ligand discovery to adsorbent development.
https://www.interphex.com/en-us/show-info/exhibitor-list/exhibitor-details.org-b595e19d-88e3-4bca-bdfd-abd834fafd2e.html#/
Jeon Seung-ho CEO Affyxell
Current CEO of Daewoong Pharmaceutical
Advisor to the Future Medicine Research Foundation
Director, Korean Pharmaceutical Association
Advisory Board Member, KAIST Convergence Medical Academy
Daewoong Pharmaceutical Global Business Head
Yoo Jong-sang CSO Affyxell
Daewoong Pharmaceutical C&D Center Director
Daewoong Pharmaceutical Bio Center Director
Director, Theragen Bio Lab
Samsung Bioepis Project Manager
Kim Ki-Nam Head of Research/Exe. Director of AFX R&D Cente
Researcher, Seoul National University Natural Products Science Research Center
Daewoong Pharmaceutical Life Science Research Center Bio Innovation Office Team Leader
Daewoong Pharmaceutical Research Headquarters Cell Therapy Business Team Leader
https://www.fiercebiotech.com/biotech/bancel-says-hes-never-been-busy-amid-ma-talks-moderna-preps-life-after-covid
Novartis has put out a plea for small biotechs to swim toward its $154 billion pool.
https://www.fiercebiotech.com/biotech/biopharma-ma-2022-different-animal-drugmakers-coffers-lined-17t
We have reached a point where Big Pharma has so much cash they could basically buy the whole smid-cap universe,
https://www.nasdaq.com/articles/pfizer-biohaven-acquisition-sparks-hope-of-more-biotech-ma
Interesting to say the least ...China all over Affimer but Avacta also have Affimers I haven't seen need the experts please
http://synbip.idrblab.net/data/sbp/details/sbp000375
Eliot’s considerable experience, expertise and network will make a material difference to achieving that goal and to delivering maximum value to shareholders >>>>
I am confident that Avacta’s Affimer technology will be both disruptive and transformational in the biotech field.